Shopping Cart 0
Cart Subtotal
USD 0

Immunovia AB (IMMNOV) - Product Pipeline Analysis, 2018 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 1500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2250
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease progression, and monitoring the therapeutic responsiveness of cancers. Immunovia's IMMray can also be used for biomarker discovery through its discovery tool for proteome scanning. The company also provides IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Its therapeutic areas include cancer and autoimmune diseases such as systemic lupus erythematosus. The company collaborates with various cancer centers for conducting clinical evidence studies. Immunovia is headquartered in Lund, Sweden.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Immunovia AB

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Immunovia AB Company Overview 5

Immunovia AB Company Snapshot 5

Immunovia AB Pipeline Products and Ongoing Clinical Trials Overview 5

Immunovia AB-Pipeline Analysis Overview 7

Immunovia AB-Key Facts 7

Immunovia AB-Major Products and Services 8

Immunovia AB Pipeline Products by Development Stage 9

Immunovia AB Ongoing Clinical Trials by Trial Status 11

Immunovia AB Pipeline Products Overview 12

IMMray-Breast Cancer 12

IMMray-Breast Cancer Product Overview 12

IMMray-Prostate Cancer 13

IMMray-Prostate Cancer Product Overview 13

IMMray PanCan-d 14

IMMray PanCan-d Product Overview 14

IMMray PanCan-d Clinical Trial 15

IMMray PanCan-m Test 16

IMMray PanCan-m Test Product Overview 16

IMMray Primary Sjogren's Syndrome Assay 17

IMMray Primary Sjogren's Syndrome Assay Product Overview 17

IMMray Rheumatoid Arthritis Assay 18

IMMray Rheumatoid Arthritis Assay Product Overview 18

IMMray SLE-d Test 19

IMMray SLE-d Test Product Overview 19

IMMray Systemic Vasculitis Assay 20

IMMray Systemic Vasculitis Assay Product Overview 20

Immunovia AB-Key Competitors 21

Immunovia AB-Key Employees 22

Immunovia AB-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Immunovia AB, Recent Developments 24

May 22, 2018: Linkoping University Hospital second Swedish site in largest ever prospective multicenter clinical study for early detection of pancreatic cancer 24

May 04, 2018: Spanish major private hospital joins world's largest study of familiar risk for pancreatic cancer 24

Apr 27, 2018: Immunovia Interim report, January-March 2018 24

Apr 12, 2018: NYU School of Medicine joins PanFAM-1 prospective study for the early detection of pancreatic cancer in familiar risk groups 25

Feb 16, 2018: Spanish center Santiago de Compostela joins the largest ever prospective study into familial risk of developing pancreatic cancer 25

Feb 15, 2018: Immunovia Full Year report, January-December 2017 26

Feb 08, 2018: Massachusetts General Hospital joins PanFAM-1 Prospective Study for the Early Detection of Pancreatic Cancer in Familiar Risk Groups 26

Jan 11, 2018: Immunovia accelerates pancreas cancer study of new onset diabetics by adding Denmark's Diabetes Center for Strategic Research-DD2 27

Dec 20, 2017: Sahlgrenska University Hospital first Swedish site in the largest ever prospective clinical study for early detection of pancreatic cancer 27

Dec 18, 2017: Immunovia Initiates the World's Largest Study of New-Onset Diabetic Patients in a Prospective Pancreas Cancer Study Supported by Swelife 28

Appendix 29

Methodology 29

About GlobalData 32

Contact Us 32

Disclaimer 32


List Of Figure

List of Figures

Immunovia AB Pipeline Products by Equipment Type 6

Immunovia AB Pipeline Products by Development Stage 9

Immunovia AB Ongoing Clinical Trials by Trial Status 11


List Of Table

List of Tables

Immunovia AB Pipeline Products and Ongoing Clinical Trials Overview 5

Immunovia AB Pipeline Products by Equipment Type 6

Immunovia AB Pipeline Products by Indication 6

Immunovia AB Ongoing Clinical Trials by Trial Status 6

Immunovia AB, Key Facts 7

Immunovia AB, Major Products and Services 8

Immunovia AB Number of Pipeline Products by Development Stage 9

Immunovia AB Pipeline Products Summary by Development Stage 10

Immunovia AB Ongoing Clinical Trials by Trial Status 11

Immunovia AB Ongoing Clinical Trials Summary 11

IMMray-Breast Cancer-Product Status 12

IMMray-Breast Cancer-Product Description 12

IMMray-Prostate Cancer-Product Status 13

IMMray-Prostate Cancer-Product Description 13

IMMray PanCan-d-Product Status 14

IMMray PanCan-d-Product Description 14

IMMray PanCan-d-A Prospective Evaluation of IMMray PanCan-d Biomarker Signature Assay in Subjects with New Onset Diabetes (NOD) 15

IMMray PanCan-d-IMMray PanCan-d Utility in Patients with Abdominal Symptoms Attending Secondary Care Centres 15

IMMray PanCan-d-Validation of Early Detection Blood Test for Pancreatic Cancer 15

IMMray PanCan-m Test-Product Status 16

IMMray PanCan-m Test-Product Description 16

IMMray Primary Sjogren's Syndrome Assay-Product Status 17

IMMray Primary Sjogren's Syndrome Assay-Product Description 17

IMMray Rheumatoid Arthritis Assay-Product Status 18

IMMray Rheumatoid Arthritis Assay-Product Description 18

IMMray SLE-d Test-Product Status 19

IMMray SLE-d Test-Product Description 19

IMMray Systemic Vasculitis Assay-Product Status 20

IMMray Systemic Vasculitis Assay-Product Description 20

Immunovia AB, Key Employees 22

Immunovia AB, Subsidiaries 23

Glossary 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Immunovia AB, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

Akinion Pharmaceuticals AB

Active Biotech AB

Moberg Pharma AB

Alligator Bioscience AB